Ardelyx
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and ...
Latest News
3 months ago · seekingalpha.com
Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call TranscriptArdelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript
3 months ago · zacks.com
Compared to Estimates, Ardelyx (ARDX) Q2 Earnings: A Look at Key MetricsWhile the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
3 months ago · marketbeat.com
Ardelyx Q2 Earnings Call HighlightsArdelyx NASDAQ: ARDX reported second-quarter product revenue of $118 million, up 31% from a year earlier and representing the company's largest quarterly revenue total to date. The company lowered its 2026 revenue outlook for IBSRELA while maintaining its forecast for XPHOZAH, citing increased payer restrictions affecting patient access to IBSRELA.
4 months ago · zacks.com
New Strong Sell Stocks for July 29thARDX, BDORY and AXSM have been added to the Zacks Rank #5 (Strong Sell) List on July 29, 2026.
4 months ago · globenewswire.com
Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that management will host a webcast and conference call on Thursday, August 6, 2026, at 4:30 p.m.
5 months ago · fool.com
Ardelyx Stock Up 70%: What to Know About This $490,000 Insider TransactionAccording to an SEC filing, an executive at Ardelyx reported selling 81,898 directly held Common Stock shares on June 18, 2026, generating a transaction value of $490,000. The sale represented 17.8% of Williams's direct Common Stock holdings, reducing her Common Stock position to 378,195 shares (direct) post-transaction.
6 months ago · marketbeat.com
Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within ReachArdelyx NASDAQ: ARDX executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to invest in its pipeline and positioning the business for sustainable profitability.
6 months ago · globenewswire.com
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in a fireside chat at the Jefferies Global Healthcare Conference 2026 on June 3 at 9:55 a.m. ET in New York.
6 months ago · seekingalpha.com
Ardelyx: Low Price, But High Implied ValuationArdelyx (ARDX) is rated Buy, driven by robust commercial execution of IBSRELA and XPHOZAH, and management's $1B revenue target by FY2029. ARDX's ACCEL Phase III trial offers significant upside optionality, potentially tripling IBSRELA's addressable market if successful. DCF analysis yields a base-case share price of $24.27, well above current levels, even excluding ACCEL trial upside.
6 months ago · globenewswire.com
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical MeetingsWALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the presentation of a data analysis evaluating the long-term impact of XPHOZAH® (tenapanor) on serum electrolytes and selected nutrition biomarkers at the National Kidney Foundation's (NKF) Spring Clinical Meetings, currently underway in New Orleans.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ARDX